Global Cerebral Artery Syndrome Treatment Market Highlights over 2022 – 2030

The global cerebral artery syndrome treatment market is estimated to grow at a notable CAGR over the forecast period, i.e., 2022 – 2030. The growth of the market can be attributed to the increasing incidences of stroke, along with growing geriatric population across the globe. Cerebral artery is the terminal branch of internal carotid artery, which supplied blood to the frontal, temporal, and parietal lobes of the brain.  Cerebral artery syndrome refers to the blockage of cerebral artery, obstructing blood supply to the middle brain. This causes hindrance to various functions controlled by this part of the brain, such as, primary motor of the face, trunk, and upper limbs. The causes of cerebral artery syndrome include hypertension, uncontrolled diabetes, smoking, fatty diet, and stressful lifestyle. According to the data by the International Diabetes Federation, approximately 463 million adults aged 20 to 79 years were suffering from diabetes in 2019, disturbingly this number will rise to 700 million by 2045. According to the data by the World Health Organization, around 1.28 billion adults suffer from hypertension, globally, as of 2021. Moreover, 46% adults are unaware that they have hypertension. It is more common in older adults, owing to the high levels of bad cholesterol in their bodies, and lack of physical activities. This is estimated to boost the market growth.

Get more information on this report: Download Sample PDF

The market is segmented by distribution channel into hospital, specialty clinic, pharmacies, and others, out of which, the hospital segment is anticipated to hold the notable share in the global cerebral artery syndrome treatment market over the forecast period on account of growing patient pool of this syndrome, and presence of large number of hospitals providing advance healthcare services. Hospitals have higher acceptance amongst the public, which is estimated to boost the market growth. 

Major Macro-Economic Indicators Impacting the Market Growth

According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.

Global Cerebral Artery Syndrome Treatment Market Regional Synopsis

On the basis of geographical analysis, the global cerebral artery syndrome treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in the North America region is anticipated to gain the largest market share throughout the forecast period owing to the increasing population of older adults, and favorable healthcare reimbursement and insurance policies. The market in Asia Pacific region is estimated to witness noteworthy growth over the forecast period on the back of highest geriatric population in the highly-populated countries, such as, India and China. According to the data by the World Bank, in India, 6.574% of the total population aged above 65 years, in 2020. Similarly, in China, 11.96% of the total population aged above 65 years in the same year. This is estimated to boost the regional market growth.

Get more information on this report: Download Sample PDF

The global cerebral artery syndrome treatment market is further classified on the basis of region as follows:

• North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
• Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
• Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
• Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis
• Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis

Market Segmentation

Our in-depth analysis of the global cerebral artery syndrome treatment market includes the following segments:

By Treatment

• Medication
• Surgery 
• Others

By Distribution Channel

• Hospital
• Specialty Clinic
• Pharmacies
• Others

Growth Drivers

• Rising Geriatric Population of the World
• Increasing Prevalence of Diabetes and Hypertension
• Poor Lifestyle and Habits of the Population

Challenges

• Lack of Healthcare Facilities in Low-Income Economies

Top Featured Companies Dominating the Market

• Abbott Laboratories
  • Company Overview
  • Business Strategy
  • Key Product Offerings
  • Financial Performance
  • Key Performance Indicators
  • Risk Analysis
  • Recent Development
  • Regional Presence
  • SWOT Analysis 
• Merck & Co., Inc.
• Pfizer, Inc.
• Siemens Healthcare GmbH
• Boehringer Ingelheim International GmbH
• Johnson & Johnson Services, Inc.
• Baxter International, Inc.
• Novartis AG
• Sanofi-aventis Groupe
• AbbVie Inc.